Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arecor Therapeutics PLC ( (GB:AREC) ) has provided an update.
Arecor Therapeutics will showcase its emerging diabetes and cardiometabolic pipeline at two major industry gatherings, underscoring its ambitions in advanced insulin therapies and drug delivery technologies. The company is positioning its lead candidate, AT278, as a disruptive ultra-concentrated, ultra-rapid insulin to support next-generation automated insulin delivery systems and high-need diabetes patients.
Chief executive Sarah Howell and chief scientific officer Jan Jezek will attend the American Diabetes Association 2026 Scientific Sessions in New Orleans, where AT278 will be highlighted among cutting-edge diabetes innovations. Business development leader Jalini Gugagayanan will represent Arecor at the BIO International Convention in San Diego, aiming to deepen industry relationships and secure potential partnerships that could accelerate commercialisation and broaden the reach of Arecor’s technology platforms.
Spark’s Take on AREC Stock
According to Spark, TipRanks’ AI Analyst, AREC is a Neutral.
The score is held down primarily by weak financial performance (sharp 2025 revenue decline, continued operating losses, and ongoing cash burn) and bearish technical signals (below major moving averages with negative MACD). A low-debt balance sheet provides some stability, but valuation is not a clear positive due to negative earnings and no dividend support.
To see Spark’s full report on AREC stock, click here.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a Cambridge-based clinical-stage biotech company focused on developing superior therapeutics to reduce treatment burden and improve outcomes for people with diabetes, obesity and other cardiometabolic diseases. Its lead product, AT278, is an ultra-concentrated, ultra-rapid acting insulin co-developed with Sequel Med Tech, and it is also advancing an oral peptide delivery platform targeting GLP-1 receptor agonists.
Average Trading Volume: 13,607
Technical Sentiment Signal: Sell
Current Market Cap: £24.92M
For a thorough assessment of AREC stock, go to TipRanks’ Stock Analysis page.